Ductal Carcinoma In Situ (DCIS)

Assessment of Stromal Features in DCIS Requires Robustness

Assessment of Stromal Features in DCIS Requires Robustness

By

Robustness of dichotomous assessment is important when evaluating stromal features of ductal carcinoma in situ (DCIS), according to a study presented at SABCS 2016.

Hormone Receptor Test Results in DCIS Core Needle Biopsy Not Used, Not Needed

Hormone Receptor Test Results in DCIS Core Needle Biopsy Not Used, Not Needed

By

Routine testing for hormone receptors in tissue obtained in a first needle biopsy for ductal carcinoma in situ (DCIS).

New Guidelines Establish Safe Surgery Margins for DCIS

New Guidelines Establish Safe Surgery Margins for DCIS

Consensus guideline states that a 2 mm margin is enough to guard against recurrences while reducing need for additional operations for women with DCIS who undergo breast-conserving surgery.

Ratio of Biomarkers on Imaging Identifies Aggressiveness of DCIS

By

A new technique combines imaging and mathematics to identify aggressive forms of ductal carcinoma in situ (DCIS), or stage 0 breast cancer, from nonaggressive varieties.

Tailoring Decisions on Radiation Therapy for DCIS

By

Decisions about radiotherapy after breast-conserving surgery for ductal carcinoma in situ can be tailored on the basis of patient factors, tumor biology, and the prognostic score, according to research.

Age, Surgery, Radiation Associated With Tamoxifen Initiation After DCIS

Age, Surgery, Radiation Associated With Tamoxifen Initiation After DCIS

By

Age, surgery, and radiation were associated with the initiation of tamoxifen after ductal carcinoma in situ (DCIS).

Active Surveillance Is Appropriate in Certain Patients With Ductal Carcinoma in Situ

By

Active surveillance could be a viable alternative to surgery and radiation for select patients with ductal carcinoma in situ (DCIS).

Screen and Detection for Early Stage Breast Cancers May Prevent Invasive Disease

By

Screening for and treatment of ductal carcinoma in situ (DCIS) is found to prevent subsequent invasive cancer.

Aggressive Ductal Carcinoma More Likely in Older Individuals

Aggressive Ductal Carcinoma More Likely in Older Individuals

Ductal Carcinoma (DCIS) is more likely to become invasive in people over 60 years old.

Study examines breast cancer mortality rate after diagnosis of ductal carcinoma in situ

By

Researchers estimate the 20-year breast cancer-specific death rate for women diagnosed with ductal carcinoma in situ to be 3.3%.

For patients with DCIS, risk of death higher for women under 35, black women

For patients with DCIS, risk of death higher for women under 35, black women

Women diagnosed with ductal carcinoma in situ have a 20-year breast cancer-specific death rate of 3.3%.

Effect of radiotherapy on survival of women with locally excised ductal carcinoma in situ of the breast: a Surveillance, Epidemiology, and End Results population-based analysis

Effect of radiotherapy on survival of women with locally excised ductal carcinoma in situ of the breast: a Surveillance, Epidemiology, and End Results population-based analysis

[OncoTargets and Therapy] This research examines the effect of radiotherapy on overall survival in women with locally excised ductal carcinoma in situ (DCIS).

Axillary lymph node evaluation performed frequently in DCIS

Axillary lymph node evaluation performed frequently in DCIS

By

Although not usually recommended for women with localized cancer undergoing breast-conserving surgery, axillary lymph node evaluation is performed frequently in women with ductal carcinoma in situ (DCIS) breast cancer.

Multigene test can predict risk of recurrence for women with ductal carcinoma in situ

By

A multigene test was validated as a predictor of risk of disease recurrence among women treated with breast-conserving surgery alone for ductal carcinoma in situ (DCIS), according to data from a large study.

Gel formulation of tamoxifen significantly reduces side effects related to the oral formulation

By

A gel form of tamoxifen applied to the breasts of women with noninvasive breast cancer reduced the growth of cancer cells to the same degree as the drug taken in oral form but with fewer side effects.

Treatment priorities set for early breast tumors

By

A team of stakeholders has detailed research priorities necessary to address gaps in knowledge about early breast tumors in women.

Local recurrence less likely after radiotherapy for DCIS

By

In women with ductal carcinoma in situ (DCIS), breast-conserving treatment combined with radiotherapy reduces the risk for local recurrence (LR), a recent study indicates.

Terminology describing DCIS affects patients' treatment preferences

Terminology describing DCIS affects patients' treatment preferences

By

When ductal carcinoma in situ (DCIS, a preinvasive malignancy of the breast) is described as a high-risk condition rather than cancer, more women report that they would opt for nonsurgical treatments.

ASCO: Use of peri-op MRI doesn't lower LRR rates

ASCO: Use of peri-op MRI doesn't lower LRR rates

No significant difference in five-, eight-year locoregional recurrence rates with, without MRI

Terminology for DCIS influences patient choices

Terminology for DCIS influences patient choices

Patients more likely to choose nonsurgical option when DCIS is described as breast lesion or abnormal cells.

Genomic scoring helps predict ductal carcinoma recurrence for patients with breast cancer

Genomic scoring helps predict ductal carcinoma recurrence for patients with breast cancer

By

Physicians have a new resource for managing disease in patients with early-stage breast cancer.

Quantifying heterogeneity in breast cancer

By

Later-stage breast cancers tend to have more mutations and are more heterogeneous than early-stage cancers. Now, new findings demonstrate that heterogeneity is prevalent even within legions of DCIS.

Study provides insight into the progression and invasiveness of ductal breast cancer

By

Despite an enormous degree of intercellular heterogeneity in both ductal carcinoma in situ and invasive ductal carcinoma, recurrent patterns of genomic imbalances determine the evolution from noninvasive to invasive disease in most cases.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs